Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Inovio Pharmaceuticals IncTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Oxford Lane Capital Corp trades at $9.54 (market cap $909.61M). The key difference: Oxford Lane Capital Corp is far larger — about 11.6× Inovio Pharmaceuticals Inc's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOOXLC
Market Cap
$78.55M$909.61M
Sector
HealthFinancials
52-Week High
$2.87$18.75
52-Week Low
$0.66$8.15
Enterprise Value
$49.56M
Dividend Yield
25.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Oxford Lane Capital Corp

OXLC trades at $9.51, up 2.59% today, with a bullish technical signal from moving averages but a neutral RSI. The stock shows mixed fundamentals: a low P/B of 0.88 suggests undervaluation, but negative ROE and ROA highlight profitability challenges. Recent earnings misses and a sharp revenue decline in 2026 contrast with consistent $0.20 monthly dividends. News sentiment is divided, with some highlighting high yield opportunities and others warning of NAV erosion and unsustainable payouts.

The outlook is cautious due to earnings volatility and high yield sustainability concerns. Opportunities include deep discount to book value and analyst buy ratings, but risks involve persistent net income losses, negative cash flow from operations, and potential dividend cuts if NAV declines continue.

Returns comparison

Trailing returns across standard periods

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC